S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

About this Study

This study compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma,

Sponsor Protocol ID:S1826
IRB Number:2019-0206
Actively Enrolling
Phase 3
July 12, 2022
Eligibility Criteria
12 years old
Both Male and Female

Inclusion Criteria
  • Histologically confirmed newly diagnosed, previously untreated stage III or IV classical Hodgkin lymphoma (nodular sclerosing, mixed cellularity, lymphocyte-rich or lymphocyte-depleted, or not otherwise specified [NOS]).
  • Bidimensionally measurable disease
  • Must have a whole body or limited whole body PET-CT scan performed within 42 days prior to registration
  • Must not receive a live vaccine within 30 days prior to planned day 1 of protocol therapy

Exclusion Criteria
  • Nodular lymphocyte predominant Hodgkin lymphoma
  • Prior chemotherapy , radiation, or antibody-based treatment for classical Hodgkin lymphoma.  Steroid pre-treatment is permitted
  • Prior solid organ transplant
  • Prior allogeneic stem cell transplant

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Elkins, Stephanie L, M.D.
How to participate in our Clinical Trials